Search our clinical trials
Cancer Treatment Centers of America® (CTCA) is committed to providing new and innovative treatments for our cancer patients whenever possible. This includes enrolling qualified patients in carefully selected clinical trials for cancer. Clinical trials are a key testing ground for determining the effectiveness and safety of new treatments and drugs for cancer and other diseases. Our doctors may recommend that cancer patients enroll in cancer clinical trials if they meet specific criteria. Cancer trials may offer patients access to treatment options that would otherwise be unavailable to them. Talk to your doctor about whether a cancer trial is a good option for you and ask about the risks and various requirements involved. Use the tool below to find a CTCA® clinical trial for your cancer type.
Merck KEYNOTE-756: A randomized, double-blind, phase 3 study of pembrolizumab versus placebo in combination with neoadjuvant chemotherapy and adjuvant endocrine therapy for the treatment of high-risk, early-stage estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer
The purpose of this study is to assess the efficacy and safety of pembrolizumab vsersus placebo in combination with neoadjuvant (pre-surgery) chemotherapy and adjuvant (post-surgery) endocrine therapy in the treatment of adults who have high-risk early-stage estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) breast cancer.
Novartis CLEE011012301C: A phase 3, multi-center, randomized, open-label trial to evaluate efficacy and safety of ribociclib with endocrine therapy as an adjuvant treatment in patients with hormone receptor-positive, HER2-negative early breast cancer (new adjuvant trial with ribociclib [LEE011]: NATALEE)
A phase 3 multi-center, randomized, open-label trial to evaluate the efficacy and safety of ribociclib with endocrine therapy as adjuvant treatment in patients with HR-positive, HER2-negative early breast cancer.
Xenera-1: A multi-centre, double-blind, placebo-controlled, randomised phase II trial to compare efficacy of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in post-menopausal women with HR+ / HER2- metastatic breast cancer and non-visceral disease
The main objective of the trial is to assess the anti-tumor activity of xentuzumab in combination with everolimus and exemestane over everolimus and exemestane in post-menopausal patients with HR+/ HER2- advanced or metastatic breast cancer and non-visceral disease.
Colorectal cancer metastatic dMMR immuno-therapy (COMMIT) study: A randomized phase III study of mFOLFOX6/bevacizumab combination chemotherapy with or without atezolizumab or atezolizumab monotherapy in the first-line treatment of patients with deficient DNA mismatch repair (dMMR) metastatic colorectal cancer
This randomized phase III trial studies how well combination chemotherapy, bevacizumab, and/or atezolizumab work in treating patients with deficient deoxyribonucleic acid (DNA) mismatch repair colorectal cancer that has spread to other places in the body.
KEYNOTE 811: A phase III, randomized, double-blind trial comparing trastuzumab plus chemotherapy and pembrolizumab with trastuzumab plus chemotherapy and placebo as first-line treatment in participants with HER2 positive advanced gastric or gastroesophageal junction adenocarcinoma
The study will compare the efficacy and safety of pembrolizumab plus trastuzumab in combination with standard of care (SOC) chemotherapy versus trastuzumab in combination with SOC chemotherapy in participants with HER2-positive gastric cancer. The primary hypotheses of the study are that pembrolizumab plus trastuzumab in combination with chemotherapy is superior to trastuzumab plus chemotherapy in terms of 1) progression free survival (PFS) per Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) as assessed by blinded independent central review (BICR), and 2) overall survival (OS).
Safety and efficacy of tipifarnib in head and neck cancer with HRAS mutations and impact of HRAS on response to therapy (AIM-HN/SEQ-HN) (KO-TIP-007)
This is an international, multicenter, open-label, 2 cohort, non-comparative, pivotal study evaluating the efficacy of tipifarnib in HRAS mutant HNSCC (AIM-HN). The first cohort will assess the objective response rate (ORR) of tipifarnib in subjects with HNSCC with HRAS mutations. The second study cohort, SEQ-HN, is an observational sub-study and includes 2 types of patients: (1) the historical record of first line therapy in subjects with HRAS mutant HNSCC participating in Cohort 1 in whom first line outcome data are available and (2) matched control HNSCC patients in whom HRAS mutations were not identified (wild type HRAS HNSCC) and who consent to provide first line outcome data and additional follow up.
AREN1721: A randomized, phase 2 trial of axitinib/nivolumab combination therapy vs. single-agent axitinib or nivolumab for the treatment of TFE/translocation renal cell carcinoma (tRCC) across all age groups
This phase II trial studies how well axitinib and nivolumab works in treating patients with TFE/translocation renal cell carcinoma that cannot be removed by surgery or has spread to other places in the body.
ARRAY-818-202: An open-label study of encorafenib + binimetinib in patients with BRAFV600E-mutant non-small cell lung cancer
This is an open-label, multicenter, non-randomized, Phase 2 study to determine the safety, tolerability and efficacy of encorafenib given in combination with binimetinib in patients with BRAFV600E-mutant metastatic non-small cell lung cancer (NSCLC).
A study of tepotinib plus osimertinib in epidermal growth factor receptor (EGFR ) tyrosine kinase inhibitor (TKI) relapsed mesenchymal-epithelial transition factor (MET) amplified non-small cell lung cancer (INSIGHT2
This study will assess the antitumor activity, safety, tolerability, and pharmacokinetics (PK) of the MET inhibitor tepotinib combined with the 3rd generation EGFR inhibitor osimertinib in participants with advanced or metastatic NSCLC.
IPSEN (RESILIENT): A randomized, open-label phase III study of irinotecan liposome injection (ONIVYDE®) versus topotecan in patients with small cell lung cancer who have progressed on or after platinum-based first-line therapy
The study will be conducted in two parts:
The purpose of part 1 is to assess the safety and tolerability of irinotecan liposome injection monotherapy and to determine the irinotecan liposome injection monotherapy dose for part 2 of the study.
The purpose of part 2 is to assess irinotecan liposome injection versus intravenous topotecan in patients with small cell lung cancer who have progressed on or after platinum-based first-line therapy.
